We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$39.3B
1-Year Est. Return
27.96%
This Fund
S&P 500
This Quarter
Est. Return
+13.03%
1 Year Est. Return
+27.96%
3 Year Est. Return
+58.37%
5 Year Est. Return
+80.22%
10 Year Est. Return
+439.89%
AUM
$39.3B
AUM Growth
+$3.7B
(+10%)
Cap. Flow
+$2.27B
Cap. Flow
% of AUM
5.78%
Top 10 Holdings %
Top 10 Hldgs %
11.24%
Holding
2,749
New
386
Increased
1,048
Reduced
996
Closed
125
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lowe's Companies
LOW
|
+$393M |
| 2 |
AngloGold Ashanti
AU
|
+$356M |
| 3 |
General Dynamics
GD
|
+$348M |
| 4 |
NVIDIA
NVDA
|
+$202M |
| 5 |
Kroger
KR
|
+$198M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$441M |
| 2 |
CVS Health
CVS
|
+$424M |
| 3 |
United Parcel Service
UPS
|
+$359M |
| 4 |
Devon Energy
DVN
|
+$243M |
| 5 |
Target
TGT
|
+$194M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.71% |
| 2 | Miscellaneous | 16.91% |
| 3 | Healthcare | 12.7% |
| 4 | Consumer Discretionary | 10.42% |
| 5 | Communication Services | 7.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1226
Kymera Therapeutics
KYMR
$9.76B
| $68K | ﹤0.01% |
+589
| New | +$50.6K |
|
1227
Unity
U
$18.3B
| $68K | ﹤0.01% |
2,367
-259
| -10% | -$6.89K |
|
1228
Viking Therapeutics
VKTX
$4.07B
| $65K | ﹤0.01% |
+1,661
| New | +$53.7K |
|
1229
Praxis Precision Medicines
PRAX
$9.82B
| $64K | ﹤0.01% |
+192
| New | +$60.8K |
|
1230
Erasca
ERAS
$5.66B
| $63K | ﹤0.01% |
+3,448
| New | +$49.3K |
|
1231
CG Oncology
CGON
$6.62B
| $60K | ﹤0.01% |
+839
| New | +$54.8K |
|
1232
Revolution Medicines
RVMD
$45B
| $60K | ﹤0.01% |
+320
| New | +$46.7K |
|
1233
Rhythm Pharmaceuticals
RYTM
$7.07B
| $60K | ﹤0.01% |
+538
| New | +$48.6K |
|
1234
Dianthus Therapeutics
DNTH
$6.05B
| $59K | ﹤0.01% |
+603
| New | +$52.7K |
|
1235
Natera
NTRA
$47.3B
| $59K | ﹤0.01% |
216
+215
| +21,500% | +$45.8K |
|
1236
Vaxcyte
PCVX
$9.1B
| $59K | ﹤0.01% |
+1,015
| New | +$55.1K |
|
1237
SELLAS Life Sciences
SLS
$2.8B
| $59K | ﹤0.01% |
+4,006
| New | +$27.7K |
|
1238
Scholar Rock
SRRK
$6.74B
| $58K | ﹤0.01% |
+1,046
| New | +$50.5K |
|
1239
Bread Financial
BFH
$4.26B
| $57K | ﹤0.01% |
524
-90
| -15% | -$8.08K |
|
1240
Cogent Biosciences
COGT
$6.03B
| $57K | ﹤0.01% |
+1,469
| New | +$51.4K |
|
1241
Mirum Pharmaceuticals
MIRM
$6.15B
| $57K | ﹤0.01% |
+490
| New | +$49.2K |
|
1242
Ultragenyx Pharmaceutical
RARE
$1.51B
| $57K | ﹤0.01% |
+1,698
| New | +$42.2K |
|
1243
Kulicke & Soffa
KLIC
$4.27B
| $56K | ﹤0.01% |
418
-28
| -6% | -$2.74K |
|
1244
Travere Therapeutics
TVTX
$6.15B
| $56K | ﹤0.01% |
+986
| New | +$43.7K |
|
1245
Celcuity
CELC
$4.68B
| $55K | ﹤0.01% |
+522
| New | +$60.2K |
|
1246
Enphase Energy
ENPH
$4.81B
| $55K | ﹤0.01% |
1,116
-129
| -10% | -$5.88K |
|
1247
Relay Therapeutics
RLAY
$4.17B
| $55K | ﹤0.01% |
+2,919
| New | +$42.4K |
|
1248
Spyre Therapeutics
SYRE
$7.85B
| $55K | ﹤0.01% |
+614
| New | +$44.8K |
|
1249
Beam Therapeutics
BEAM
$3.06B
| $54K | ﹤0.01% |
+1,563
| New | +$47.2K |
|
1250
Insmed
INSM
$27.6B
| $54K | ﹤0.01% |
502
-6,777
| -93% | -$821K |
|
Similar funds
PPF
CS
Pacer Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Pacer Advisors held 2,749 positions worth $39.3B, up 10% from $35.6B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Pacer Advisors deployed $2.27B of net new capital in Q2 2026, opening 386 new positions and adding to 1,048 existing holdings. Its largest new stake was AngloGold Ashanti: 3,744,168 shares worth $303M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 22% a quarter earlier, followed by Miscellaneous and Healthcare.
On the sell side, the largest reduction was ConocoPhillips, an estimated $441M trimmed.
- Pacer Advisors's largest Q2 2026 buy was AngloGold Ashanti: 3,744,168 shares worth $303M.
- Pacer Advisors added most to Lowe's Companies in Q2 2026, an estimated $393M increase.
- Pacer Advisors's biggest Q2 2026 reduction was ConocoPhillips, cutting an estimated $441M.
- Pacer Advisors fully exited Coterra Energy in Q2 2026, selling an estimated $118M.
- Pacer Advisors's ten largest holdings make up 11% of its $39.3B portfolio in Q2 2026.
- Pacer Advisors opened 386 new positions and closed 125 in Q2 2026.
- Pacer Advisors's portfolio value rose 10% quarter-over-quarter to $39.3B.
Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.